Teva debuts generic Azopt

Teva is launching brinzolamide ophthalmic suspension, 1%.

The product is the first-to-market generic of Novartis' Azopt (brinzolamide ophthalmic suspension).

It is used to treat elevated pressure within the eye in people with high pressure within the eye or open-angle glaucoma. It works by decreasing the amount of fluid within the eye.

“This first-to-market generic version of Azopt (brinzolamide ophthalmic suspension) 1% in the United States provides patients with another important treatment option,” said Christine Baeder, senior vice president, chief operating officer of US Generics, Teva USA. “Continuing to pursue much-needed generic drugs is critical to ensuring access to quality medicines to everyone who needs them.”

Brinzolamide ophthalmic suspension 1% has a market value of more than $184 million, according to IQVIA December 2020 data.